SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " wegovy " 57 found 🔀 AI-powered Shuffle
Would subsidizing weight-loss drugs make health care fairer?
GLP-1 medicines such as Ozempic, Wegovy and Mounjaro have transformed the treatment of obesity, but access to them in Australia increasingly depends on something much less medical: whether you can afford ...
Ozempic and Wegovy linked to rare risk of sudden vision loss
Popular diabetes and weight loss drugs such as Ozempic and Wegovy have been linked to a slightly increased risk of a rare condition that can cause sudden, potentially permanent vision loss. Although the risk remains very low, Rutgers researchers say the findings warrant attention as millions of people turn to GLP-1 medications.
Popular weight loss drugs linked to a surprising fingernail problem
Popular GLP-1 weight loss drugs, such as Ozempic and Wegovy, have been linked to unexpectedly high rates of nail detachment, hair loss, and scalp inflammation, with some problems occurring several times more frequently among users. Researchers found that weight loss alone could not fully explain the differences, suggesting there may be more to these overlooked symptoms.
Rapid weight loss on popular drugs could ‘starve’ the brain, expert warns
Dr. Tommy Wood warns GLP-1 drugs like Ozempic and Wegovy can shrink brain tissue when caloric restriction cuts off vital energy the brain needs.
FSU HEALTH COMMUNICATION EXPERT FINDS GLP-1 USERS FACE STIGMA WITHIN THEIR SOCIAL CIRCLES
Sept 24 2026 – People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a Florida State University professor. Braidyn Lazenby, an assistant professor at FSU’s College of Communication & Information, led the study “‘They Call Us Cheaters:” Exploring Stigma […]
FSU Health Communication expert finds GLP-1 users face stigma within their social circles
People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a
Ozempic and Wegovy may have an unexpected mental health benefit
Semaglutide, the drug behind Ozempic and Wegovy, may have benefits that extend well beyond weight loss and diabetes. In a large Swedish study of nearly 15,000 people with bipolar disorder, its use was linked to a 21% lower risk of psychiatric hospitalization. Researchers think effects on inflammation and brain-related biological pathways could help stabilize mood, though other GLP-1 drugs did not show the same association.
Experimental compound helps burn fat without muscle loss
A decades-old compound may point to a new way of treating obesity by making the body burn more energy rather than simply reducing appetite. In mice, TOFA increased energy use by as much as 18%, reduced body fat without significant muscle loss, and improved blood sugar, triglycerides, and fatty liver disease. It also produced stronger results when combined with GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound.
Wegovy and Zepbound are changing how Americans get health care
Ozempic, Wegovy and Zepbound have helped Americans lose weight, cut demand for weight-loss operations and improved heart health.
Scientists solve the mystery of a brain “switch” that can trigger weight loss in opposite ways
Scientists have uncovered why two seemingly opposite ways of targeting the same brain receptor can both promote weight loss. In mice, activating the GIP receptor in the brainstem reduced appetite, while blocking it in the hypothalamus removed a kind of “brake” on fullness signals. The discovery helps explain why very different obesity drugs can achieve similar results and suggests that carefully combining GIP-targeting treatments with GLP-1 drugs like those related to Wegovy and Ozempic could produce stronger effects.
Compounded Semaglutide vs. Wegovy For Weight Loss: What You Need To Know
Compounded Semaglutide vs. Wegovy For Weight Loss: What You Need To Know
Wegovy, weight loss and cardiovascular health: A closer look at how semaglutide protects the heart
When patients take semaglutide, the dose appears to offer more cardiovascular benefits than weight loss.
GLP-1 drug popularity is outpacing the science, Madison doctor says
Dr. David Harris at UW-Madison says weight loss drugs like Ozempic, Wegovy and Zepbound are safe, so long as patients get the medications from doctors.
The Ozempic and Wegovy mistake sending thousands to poison control
Poison control calls involving semaglutide (Ozempic and Wegovy) soared after the drug was approved for weight management, with researchers linking the increase to accidental dosing mistakes rather than intentional misuse. Simple education about proper weekly dosing and gradual dose increases could help prevent many of these avoidable incidents.
New weight loss pill beats oral Ozempic in major trial
A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements than the leading oral semaglutide in a major clinical trial. The tablet could offer a more convenient alternative to injectable drugs like Ozempic and Wegovy because it doesn't require refrigeration or special timing with meals. It's also cheaper to manufacture, which could expand access globally.
GLP-1s 101: What the science says about weight loss, side effects, safety
We asked Stanford Medicine experts to break down everything you need to know about the drugs known as GLP-1s, semaglutide, Ozempic, Wegovy, Zepbound and many more.
Medicare will start covering weight-loss drugs on July 1 for the first time. Here’s what you need to know
Millions of Medicare enrollees will gain their first-ever coverage for drugs for weight loss under a temporary pilot program that launches July 1.
Americans keep poisoning themselves with semaglutide, other weight loss drugs
These incidents became much more common after the FDA started approving GLP-1 drugs for chronic weight management in 2021.
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in costs, investors and analysts say.
Ozempic and Wegovy linked to surprising drop in violent behavior
A Rutgers study suggests GLP-1 drugs such as Ozempic and Wegovy may weaken the link between impulsive tendencies and violent behavior. The surprising finding hints that these medications could affect how people act on impulses, though researchers stress that cause and effect have not been proven.
People taking GLP-1 weight loss drugs like Ozempic started moving less
People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less. Researchers analyzing Fitbit data found that daily step counts and exercise levels dropped after people started these medications, despite successful weight loss. Because the drugs can reduce muscle mass along with fat, the decline in physical activity raises concerns about preserving strength and long-term health.
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and obesity treatment, a new report shows.
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help prevent breast cancer.
Scientists discover why Ozempic and Wegovy weight loss eventually plateaus
New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone. Scientists also found a possible way to extend the drugs’ effects, potentially helping patients push past weight-loss plateaus.
Wegovy linked to rare “eye stroke” that can cause sudden blindness
A new analysis is raising concerns about Wegovy, the blockbuster weight-loss drug, after researchers found it may carry the highest risk of a rare “eye stroke” that can cause sudden vision loss. The study, based on millions of FDA side-effect reports, found the risk signal was nearly five times stronger for Wegovy than for Ozempic, despite both containing semaglutide.
Weight loss medications heavy on Fort Worth’s employee health plan
Skyrocketing use of weight loss medications such as Ozempic, Wegovy and Zepbound drives up insurance claims for the city of Fort Worth.
Popular weight loss drugs like Wegovy may also target arthritis inflammation
Researchers have discovered that the GLP-1 hormone targeted by drugs like Wegovy is present in very low amounts inside the joints of arthritis patients. That finding suggests high-dose GLP-1 medications could potentially reach the joints and influence inflammation directly, not just help through weight loss. Scientists say this could open the door to a completely new approach to arthritis treatment.
People who lost the most weight on Ozempic saw huge health benefits
People who lost significant weight while taking Ozempic, Wegovy, Mounjaro, or Saxenda had sharply lower risks of major obesity-related health problems, including sleep apnea and kidney disease. Those who gained weight instead faced higher risks — especially for heart failure — even though many patients discontinued the medications within a year.
Healthy Returns: Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk
New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.
The dark side of weight loss drugs: Ozempic's surprising hidden cost
GLP-1 weight-loss drugs like Ozempic and Wegovy are often celebrated as game-changing solutions—but new research reveals a surprising social twist. People who lose weight using these medications may actually face more judgment than those who lose weight through diet and exercise—or even those who don’t lose weight at all. The stigma seems rooted in a perception that these drugs are an “easy way out,” creating a double bind where individuals are judged both for their weight and for how they choose to manage it.
Weight loss drug Ozempic linked to lower depression and anxiety risk
GLP-1 drugs like semaglutide—best known for treating diabetes and driving weight loss under the brand names Ozempic and Wegovy—may also deliver a surprising mental health boost. In a massive study tracking nearly 100,000 people over more than a decade, researchers found that these medications were linked to significantly fewer psychiatric hospital visits and sick days.
Scientists discover new enzyme that could supercharge weight-loss drugs
Researchers at the University of Utah have discovered an enzyme called Pap B that will chemically change and update drugs like Ozempic and Wegovy making them stronger and last longer.
Restrictions on obesity drug coverage force patients to pivot
Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, according to an analysis by GoodRx, a drug discount website.
Scientists discover natural hormone that reverses obesity
A hormone called FGF21 can reverse obesity in mice by activating a newly identified brain circuit tied to metabolism. Surprisingly, it works in the hindbrain—the same region targeted by GLP-1 drugs like Ozempic and Wegovy—but through a completely different mechanism. Instead of suppressing appetite, FGF21 ramps up the body’s energy burning. This insight could pave the way for more targeted weight-loss and liver disease treatments.
This CEO wants to cover weight loss drugs for employees. They're just too expensive.
As demand for GLP-1 drugs surges, employers and insurers are struggling to keep up with the cost. Some are dropping coverage altogether.
Novo Nordisk CEO: This is where science meets speed and scale
Maziar Mike Doustdar, CEO of Novo Nordisk, says AI partnership with OpenAI will speed drug discovery and delivery, boost accuracy and strengthen confidence in Wegovy despite rising competition.
Why Ozempic doesn’t work for everyone: Scientists just found a hidden reason
A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due to specific genetic variants. These individuals appear to have a puzzling condition called “GLP-1 resistance,” where their bodies produce higher levels of the hormone targeted by these drugs—but don’t respond to it properly.
Divorce boom may follow use of Ozempic and other GLP-1 drugs, experts warn
Research suggests GLP-1 drugs like Ozempic and Wegovy could double divorce risk, mirroring trends seen in bariatric surgery patients, experts say.
Demand for GLP-1 pills and shots surges, and not just for weight loss
Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S. saying they currently take the medications.
Weight-loss treatment is on the verge of a dramatic shift
About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more head-spinning change.
Ozempic Linked to Lower Risk of Plunging Mental Health in Study
Swedish people with depression and anxiety who took Novo Nordisk A/S’s blockbuster shots Ozempic and Wegovy were less likely to see their mental health get worse, the latest data to suggest that popular diabetes and obesity drugs could also have a broader impact on well-being.
Weight Loss Drugs Like Ozempic and Wegovy Show Surprising Heart Health Benefits
A new study suggests that widely used GLP-1 weight-loss drugs may do more than improve metabolic health: they could also protect the heart after a heart attack. Doctors can often reopen the blocked artery that triggers a heart attack, but that is not always the end of the crisis inside the heart
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk's Wegovy and other weight-loss drugs, ending a patent lawsuit for now.
BBC Audio | Business Daily | The worldwide weight-loss revolution
Drugs like Ozempic, Wegovy, Mounjaro and Zepbound are reshaping global obesity treatment
Novo Nordisk to halve US list price of Wegovy from 2027
Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year to $675 a month, the Danish
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows
Hedge fund bets against Hims & Hers Health hit their highest in at least a year in January, just before the online telehealth firm clashed with Novo Nordisk over its cut-price weight-loss pill, according to data shared with Reuters by Hazeltree.
Hims & Hers responds to FDA pressure, pulls knockoff Wegovy drug launch after regulatory threats
Telehealth company Hims & Hers cancels $49 monthly weight loss drug launch following FDA warnings about unapproved semaglutide compounds and Novo threats.
VIEW Hims and Hers Health's compounded Wegovy pill offering fuels market jitters
Hims & Hers said it would begin offering compounded versions of Novo Nordisk's Wegovy pill at an introductory price of $49 per month.
Exclusive: Hims and Hers Health launches copy of Wegovy pill at $49
Online telehealth company Hims and Hers Health will begin offering copies of Novo Nordisk's new Wegovy pill at an introductory price of $49 per month, the company said Thursday, about $100 less than the brand name.
Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business
Danish drug maker Novo Nordisk said on Wednesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy.
UK health regulator approves up to 7.2 mg weekly dose of Wegovy for obesity patients
Britain's health regulator approved a maximum dose of up to 7.2 miligrams per week of Novo Nordisk's blockbuster weight-loss drug Wegovy for patients with obesity only, it said on Friday.
Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill
In recent days, Amazon Pharmacy announced it would begin offering Novo Nordisk’s Wegovy once-daily weight-loss pill through both insurance and cash-pay channels, including future availability via its pharmacy kiosks. This move directly targets the fast-growing weight management segment where Hims & Hers Health participates, raising fresh questions about how differentiated and resilient its broader telehealth platform and recurring-care model really are beyond GLP-1 offerings. We’ll now...
Telehealth companies swoop in to offer Wegovy pill
In this edition of STAT's Health Tech: Telehealth jumps on the Wegovy pill bandwagon, Neuralink's grand vision collides with reality, and more
Wegovy obesity pill now available at pharmacies
Drugmaker Novo Nordisk said the prescription medicine can be found at a range of pharmacies, including CVS and Costco, as well as some telehealth providers.
A cheaper, easier-to-use version of Wegovy is coming to the US soon
Wegovy's new pill has been approved in the US, offering a needle-free option with a lower starting price than injections.
With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins
With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins